Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis
While higher pyrazinamide and isoniazid exposures and slow NAT2 acetylator status were each associated with increased hepatotoxicity, only pyrazinamide exposure was associated when considering pharmacokinetic variables together. Rifampin exposure was not associated with hepatotoxicity, supporting further evaluation of doses up to 20 mg/kg/day in a larger trial.
Authors
- Dante Vargas Vásquez
- Pieter Van Brantegem (ORCID: https://orcid.org/0000-0002-0365-5841)
- Elizabeth A. Mackay
- Elna Osso
- Karen Tintaya
- Carole Diane Mitnick (ORCID: https://orcid.org/0000-0002-3455-658X)
- Charles A. Peloquin (ORCID: https://orcid.org/0000-0001-9002-7052)
- Gustavo E. Velásquez (ORCID: https://orcid.org/0000-0003-1438-0692)
- Julia Coit (ORCID: https://orcid.org/0000-0002-9837-8444)
- Epifanio Sánchez Garavito
- Gareth Platt (ORCID: https://orcid.org/0000-0002-6687-0012)
- Geraint Davies (ORCID: https://orcid.org/0000-0002-3819-490X)
- Leonid Lecca
- Dalicxa Garcia
- Roger I Calderón
- Judith Jiménez
- Radojka M Savic
- Meredith B Brooks
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Partners In Health (US)
- University of Liverpool (GB)
- University of California, San Francisco (US)
- American Association of Colleges of Pharmacy (US)
- Universidad de San Martín de Porres (PE)
- University of California System (US)
- Hospital Nacional Cayetano Heredia (PE)
- EsSALUD (PE)
- Global Brain Health Institute (US)
- Harvard Global Health Institute (US)
- Global Solutions for Infectious Diseases (US)
- Universidad Privada Sergio Bernales (PE)
- Florida College (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1093/cid/ciag141
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00